Pharnext Past Earnings Performance
Past criteria checks 0/6
Pharnext's earnings have been declining at an average annual rate of -13.2%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been declining at an average rate of 22.4% per year.
Key information
-13.2%
Earnings growth rate
n/a
EPS growth rate
| Biotechs Industry Growth | 30.8% |
| Revenue growth rate | -22.4% |
| Return on equity | n/a |
| Net Margin | -1,733.6% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Pharnext makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 2 | -32 | 8 | 20 |
| 31 Mar 23 | 2 | -35 | 9 | 20 |
| 31 Dec 22 | 2 | -38 | 9 | 21 |
| 30 Sep 22 | 2 | -37 | 8 | 20 |
| 30 Jun 22 | 3 | -36 | 7 | 20 |
| 31 Mar 22 | 3 | -33 | 7 | 20 |
| 31 Dec 21 | 4 | -31 | 7 | 20 |
| 30 Sep 21 | 4 | -28 | 7 | 19 |
| 30 Jun 21 | 4 | -26 | 8 | 18 |
| 31 Mar 21 | 3 | -24 | 8 | 16 |
| 31 Dec 20 | 3 | -22 | 8 | 14 |
| 30 Sep 20 | 3 | -21 | 8 | 13 |
| 30 Jun 20 | 3 | -20 | 8 | 13 |
| 31 Mar 20 | 3 | -22 | 8 | 14 |
| 31 Dec 19 | 4 | -23 | 8 | 15 |
| 30 Sep 19 | 4 | -24 | 8 | 16 |
| 30 Jun 19 | 4 | -25 | 8 | 17 |
| 31 Mar 19 | 5 | -23 | 8 | 17 |
| 31 Dec 18 | 7 | -21 | 7 | 18 |
| 30 Sep 18 | 7 | -20 | 7 | 17 |
| 30 Jun 18 | 7 | -18 | 6 | 17 |
| 31 Mar 18 | 5 | -19 | 6 | 16 |
| 31 Dec 17 | 3 | -20 | 6 | 16 |
| 30 Sep 17 | 3 | -20 | 6 | 16 |
| 30 Jun 17 | 4 | -20 | 5 | 16 |
| 31 Mar 17 | 4 | -19 | 5 | 15 |
| 31 Dec 16 | 4 | -17 | 4 | 14 |
| 30 Sep 16 | 4 | -16 | 4 | 12 |
| 30 Jun 16 | 3 | -14 | 4 | 10 |
| 31 Mar 16 | 3 | -12 | 4 | 9 |
| 31 Dec 15 | 3 | -11 | 4 | 8 |
| 31 Dec 14 | 3 | -11 | 4 | 7 |
| 31 Dec 13 | 3 | -9 | 3 | 9 |
Quality Earnings: ALPHA is currently unprofitable.
Growing Profit Margin: ALPHA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ALPHA is unprofitable, and losses have increased over the past 5 years at a rate of 13.2% per year.
Accelerating Growth: Unable to compare ALPHA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALPHA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: ALPHA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.